BioCryst Pharmaceuticals (BCRX) said Friday that new data showed "significant and sustained" reductions in hereditary angioedema attack rates among adolescents and other patients treated with Orladeyo.

The findings were based on retrospective analyses involving 155 US patients over 18 months, the company said.

Patients with more than eight attacks monthly saw an average reduction of over six attacks per month after one year of treatment, according to the study.

In adolescents aged 12 to 17, average monthly attack rates fell by 1.56 at 12 months and by 1.85 at 18 months compared to baseline, BioCryst said.

BioCryst reported consistent reductions in attack frequency across all 90-day follow-up periods after Orladeyo initiation.

Shares of the company were up over 1.4% in recent Friday premarket activity.